Samsung Biologics Co.,Ltd. (207940.KS)
207940.KS Stock Price Chart
Explore Samsung Biologics Co.,Ltd. interactive price chart. Choose custom timeframes to analyze 207940.KS price movements and trends.
207940.KS Company Profile
Discover essential business fundamentals and corporate details for Samsung Biologics Co.,Ltd. (207940.KS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Nov 2016
Employees
4.77K
Website
https://samsungbiologics.comCEO
John Chongbo Rim
Description
Samsung Biologics Co.,Ltd. engages in the contract manufacturing organization (CMO) business for biopharmaceuticals products. The company operates in two segments, CMO and Contract Development Organization (CDO). It is involved in the provision of CDO services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company was founded in 2011 and is headquartered in Incheon, South Korea.
207940.KS Financial Timeline
Browse a chronological timeline of Samsung Biologics Co.,Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 21 Apr 2026
Upcoming earnings on 20 Jan 2026
Upcoming earnings on 22 Oct 2025
EPS estimate is ₩5.57K, while revenue estimate is ₩1.54T.
Stock split effective on 29 Sept 2025
Shares were split 13 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 22 Jul 2025
EPS came in at ₩3.35 falling short of the estimated ₩3.38 by -0.89%, while revenue for the quarter reached ₩946.79M , missing expectations by -6.47%.
Earnings released on 22 Apr 2025
EPS came in at ₩5.13K surpassing the estimated ₩3.74K by +36.92%, while revenue for the quarter reached ₩1.30T , beating expectations by +10.02%.
Earnings released on 23 Jan 2025
EPS came in at ₩4.34K surpassing the estimated ₩3.74K by +16.03%, while revenue for the quarter reached ₩1.26T , beating expectations by +6.17%.
Earnings released on 23 Oct 2024
EPS came in at ₩3.72K surpassing the estimated ₩3.43K by +8.20%, while revenue for the quarter reached ₩1.19T , missing expectations by -3.16%.
Earnings released on 24 Jul 2024
EPS came in at ₩4.47K surpassing the estimated ₩3.41K by +31.21%, while revenue for the quarter reached ₩1.16T , beating expectations by +0.24%.
Earnings released on 24 Apr 2024
EPS came in at ₩2.52K falling short of the estimated ₩2.82K by -10.74%, while revenue for the quarter reached ₩946.90B , missing expectations by -0.07%.
Earnings released on 24 Jan 2024
EPS came in at ₩4.08K surpassing the estimated ₩3.30K by +23.90%, while revenue for the quarter reached ₩1.07T , beating expectations by +1.50%.
Earnings released on 25 Oct 2023
EPS came in at ₩3.38K surpassing the estimated ₩3.22K by +4.86%, while revenue for the quarter reached ₩1.03T , beating expectations by +5.88%.
Earnings released on 26 Jul 2023
EPS came in at ₩2.60K surpassing the estimated ₩2.49K by +4.49%, while revenue for the quarter reached ₩866.18B , beating expectations by +7.60%.
Earnings released on 24 Apr 2023
EPS came in at ₩1.99K falling short of the estimated ₩2.13K by -6.42%, while revenue for the quarter reached ₩720.92B , missing expectations by -0.66%.
Earnings released on 27 Jan 2023
EPS came in at ₩5.20K surpassing the estimated ₩2.24K by +131.94%, while revenue for the quarter reached ₩965.53B , beating expectations by +19.08%.
Earnings released on 26 Oct 2022
EPS came in at ₩1.82K falling short of the estimated ₩2.39K by -24.02%, while revenue for the quarter reached ₩873.04B , beating expectations by +15.34%.
Earnings released on 27 Jul 2022
EPS came in at ₩2.15K surpassing the estimated ₩1.92K by +12.07%, while revenue for the quarter reached ₩651.42B , beating expectations by +15.33%.
Earnings released on 27 Apr 2022
EPS came in at ₩2.22K surpassing the estimated ₩1.48K by +50.35%, while revenue for the quarter reached ₩511.30B , beating expectations by +9.16%.
Earnings released on 24 Jan 2022
EPS came in at ₩1.18K falling short of the estimated ₩1.66K by -28.63%, while revenue for the quarter reached ₩444.31B .
Earnings released on 26 Oct 2021
EPS came in at ₩1.97K surpassing the estimated ₩1.65K by +18.96%, while revenue for the quarter reached ₩450.73B , beating expectations by +18.96%.
Earnings released on 27 Jul 2021
EPS came in at ₩1.82K surpassing the estimated ₩1.32K by +37.78%, while revenue for the quarter reached ₩412.16B .
Earnings released on 28 Apr 2021
EPS came in at ₩911.21 falling short of the estimated ₩1.17K by -22.41%, while revenue for the quarter reached ₩260.80B .
Earnings released on 26 Jan 2021
EPS came in at ₩1.44K surpassing the estimated ₩951.56 by +51.01%, while revenue for the quarter reached ₩375.31B .
Earnings released on 21 Oct 2020
EPS came in at ₩838.08 falling short of the estimated ₩909.03 by -7.81%, while revenue for the quarter reached ₩274.58B .
207940.KS Stock Performance
Access detailed 207940.KS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.